PepGen Inc. (PEPG): Total Liabilities
$26.46M
As of 2025-12-31
$21.86M
As of 2026-06-30
-11.2%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.46M | -18.0% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $32.26M | -6.8% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $34.63M | -8.4% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $37.81M | +258.5% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $10.55M | n/a | 2023-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | $26.46M | -18.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $32.23M | -45.6% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $20.69M | +53.8% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $7.27M | +37.0% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $5.61M | +144.2% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $10.84M | +690.3% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $33.55M | +28.6% |
Compare PEPG, GOSS, ELDN, CRBP side by side · Screen every company in Pharmaceutical Preparations ↗